Almost every diabetic patient in Indonesia that requires insulin to control their blood sugar is treated with the newer generation insulin analogue, despite internationally recognized guidance that low and middle-income countries (LMICs) should aim to use the less costly human insulin, the first generation of man-made insulin, as a first line treatment.